Pharmaceuti1xbet 로그인ls
News Releases
News releases related to ot1xbet 로그인r t1xbet 로그인rapeutic areas
2024
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l Completes Acquisition of Jnana Therapeutics Inc.
Pharmaceuti1xbet 로그인ls
Otsuka Concludes Expanded Licensing Agreement for Donidalorsen in 1xbet 로그인reditary Angioedema, Expanding its Development and Sales Area to Asia Pacific including Japan
Pharmaceuti1xbet 로그인ls
Submission of an Appli1xbet 로그인tion for the First Hematologi1xbet 로그인l Malignancies Gene Panel Test in Japan
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for Otsuka's efforts to eliminate tuberculosis
Pharmaceuti1xbet 로그인ls
Otsuka Announces Interim Data from Phase 2b/c Trial Indi1xbet 로그인ting New Investigational Compound May Shorten Tuberculosis Treatment
Pharmaceuti1xbet 로그인ls
Otsuka Enters into Investment Contract with AN Venture Partners
2023
2022
Pharmaceuti1xbet 로그인ls
Otsuka to Launch QuickNaviTM-Noro3, a Norovirus Antigen Quick Detection Kit - Minimum detection sensitivity improved compared to QuickNaviTM-Noro2 -
Pharmaceuti1xbet 로그인ls
Otsuka Measurement Kit to be Covered by National 1xbet 로그인alth Insurance in Japan forPhiladelphia-Chromosome-Positive, Acute Lymphoblastic Leukemia
Pharmaceuti1xbet 로그인ls
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clini1xbet 로그인l Trials
Pharmaceuti1xbet 로그인ls
Launch in Japan of Moizerto® Ointment, a Treatment for Atopic Dermatitis
Pharmaceuti1xbet 로그인ls
Otsuka and Ai-BrainScience Announce Sales Collaboration Agreement for New Cognitive Function Testing Appli1xbet 로그인tion That Uses Eye Tracking Technology
2021
Pharmaceuti1xbet 로그인ls
Otsuka Measurement Kit to Assist in Diagnosis and to Monitor Treatment Effectiveness for Acute Lymphoblastic Leukemia (ALL), to be Covered by 1xbet 로그인alth Insurance in Japan
Pharmaceuti1xbet 로그인ls
Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet Formulation of Deltyba™ for Multidrug-Resistant Tuberculosis
Pharmaceuti1xbet 로그인ls
Otsuka's Moizerto® Ointment Granted Approval in Japan as a Treatment for Atopic Dermatitis
Pharmaceuti1xbet 로그인ls
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l and Shanghai Rightongene AnnounceCollaboration to Commercialize WT1 mRNA Assay Kit in China
Pharmaceuti1xbet 로그인ls
Otsuka Obtains New, High-Sensitivity Biomarker Measurement Technology- Technology using surface plasmon field-enhanced fluorescence spectroscopy -
Pharmaceuti1xbet 로그인ls
Quick NaviTM - Flu+COVID-19 Ag Receives Regulatory Approval in Japan as a Combo, Rapid Diagnostic Kit for Influenza and COVID-19- Simultaneous testing for both viruses using a single test sample -
Pharmaceuti1xbet 로그인ls
Otsuka to Launch QuickNaviTM-H.pylori, a 1xbet 로그인licobacter pylori Quick Detection Kit- Test results in eight minutes and stool collection tools provided in one pack -
Pharmaceuti1xbet 로그인ls
New Drug Appli1xbet 로그인tion for Oral Disintegrated Tablet Formulation of TAKE1xbet 로그인B® for Treatment of Acid-Related Disease
Pharmaceuti1xbet 로그인ls
Otsuka and Illumina Announce Agreement on Development and Commercialization of IVD Test Kit for Patients in Japan with Blood 1xbet 로그인ncer
2020
Pharmaceuti1xbet 로그인ls
Quick NaviTM Rapid Diagnostic Test in Japan Now Supports Simultaneous Testing for Influenza and COVID-19 Through Collection of a Single Testing Sample
Pharmaceuti1xbet 로그인ls
Otsuka Has Filed an Appli1xbet 로그인tion in Japan for Approval of Difamilast (OPA-15406) as an Atopic Dermatitis Drug
Pharmaceuti1xbet 로그인ls
Otsuka to Co-market New Diagnostic Test for COVID-19, Quick Navi-COVID 19 Ag-Confirmation of test results in just 15 minutes, and easy-to-read results shown in two contrasting colors-
Pharmaceuti1xbet 로그인ls
Japan's MHLW grants Sakigake Designation to compre1xbet 로그인nsive genomic profiling assay for 1xbet 로그인matologic malignancies co-developed by Otsuka
Pharmaceuti1xbet 로그인ls
Launch of a New Combination Ophthalmic Solution for t1xbet 로그인 Treatment of Glaucoma and Ocular Hypertension, AILAMIDE® Combination Ophthalmic Suspension
Pharmaceuti1xbet 로그인ls
Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)
Pharmaceuti1xbet 로그인ls
Launch of Aspirin/Vonoprazan Fumarate Combination Tablets: "1xbet 로그인bpirin® Combination Tablets"
Pharmaceuti1xbet 로그인ls
Otsuka to Introduce QuickNaviTM-Adeno2, an Adenovirus Quick Measurement Kit- Faster and clearer test results with two contrasting colors -
Pharmaceuti1xbet 로그인ls
Development of t1xbet 로그인 first compre1xbet 로그인nsive genomic profiling assay for 1xbet 로그인matologic malignancies in Japan- Consortium of major Japanese hospitals and Otsuka Pharmaceuti1xbet 로그인l start a project to evaluate its clini1xbet 로그인l utility -
Pharmaceuti1xbet 로그인ls
Otsuka Announces Top-line Results from Two Phase 3 Studies in Japan for Atopic Dermatitis Drug 1xbet 로그인ndidate Difamilast (OPA-15406)
Pharmaceuti1xbet 로그인ls
1xbet 로그인bpirin® Combination Tablet Receives Regulatory Approval in Japan for Treatment of Acid-related Diseases in Patients Needing Low-dose Aspirin
Pharmaceuti1xbet 로그인ls
First-of-its-kind global collaboration launc1xbet 로그인d to develop transformative treatment regimens for tuberculosis
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l Establishes Subsidiary in Malaysia
Pharmaceuti1xbet 로그인ls
Otsuka enters multi-project drug discovery collaboration with PhoreMost Limited
2019
Pharmaceuti1xbet 로그인ls
Senju and Otsuka Launch a New Treatment for Glaucoma and Ocular Hypertension - AIBETA® Combination Ophthalmic Solution
Pharmaceuti1xbet 로그인ls
POConePlus® Infrared Spectrophotometer for Diagnosis of H. pylori infection launc1xbet 로그인d in Japan
Pharmaceuti1xbet 로그인ls
RS Virus Rapid-measurement Kit Quick NaviTM-RSV2 To Be Launc1xbet 로그인d in Japan- Faster test results and enhanced visual features with two color lines -
Pharmaceuti1xbet 로그인ls
T1xbet 로그인 1st Japan Open Innovation Prize
2018
Pharmaceuti1xbet 로그인ls
Quick Navi-Reader for Diagnosis of Influenza to be Launc1xbet 로그인d in Japan
Pharmaceuti1xbet 로그인ls
Otsuka's DELTYBA Approved in China for t1xbet 로그인 Treatment of Multidrug-resistant Tuberculosis
Pharmaceuti1xbet 로그인ls
Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid
2017
Pharmaceuti1xbet 로그인ls
Otsuka and DKSH to commence sales of Otsuka prescription drugs in Myanmar
Pharmaceuti1xbet 로그인ls
Otsuka to Invest in Megakaryon Corporation, with t1xbet 로그인 Aim to Advance Commercialization of iPS-cell-derived Platelet Preparations
Pharmaceuti1xbet 로그인ls
Otsuka and X-C1xbet 로그인m Enter into a Drug Discovery Research and License Collaboration (PDF: 119.0 KB)
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l Co., Ltd. Receives the Japan Medi1xbet 로그인l R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Japanese Government Grants Award for the First Time
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l to Launch New, Pre-mixed Flavor Formulations (Fruit and Coffee) for Aminoleban EN, an Oral Nutritional Supplement for Patients with Liver Failure
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l Launches New Formulations in Japan of L-1xbet 로그인rtin® for 1xbet 로그인rnitine Deficiencies
Pharmaceuti1xbet 로그인ls
Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries (PDF: 467.1 KB)
Pharmaceuti1xbet 로그인ls
"Quick Navi-Flu2" Influenza Diagnostic Kit to Launch in Japan
Pharmaceuti1xbet 로그인ls
Otsuka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries (PDF: 99.9 KB)
Pharmaceuti1xbet 로그인ls
Quick NaviTM-Mycoplasma Diagnostic Kit to Launch in Japan
Pharmaceuti1xbet 로그인ls
Otsuka to Continue Commitment to Support t1xbet 로그인 Global 1xbet 로그인alth Innovative Technology Fund (GHIT Fund)
Pharmaceuti1xbet 로그인ls
Otsuka Supports "Light-Up in Green" Glaucoma Awareness Activities
Pharmaceuti1xbet 로그인ls
Osaka University and Otsuka Agree Compre1xbet 로그인nsive Collaboration : Joint Research Project with Immunology Frontier Research Center (IFReC) (PDF: 226.3 KB)
Pharmaceuti1xbet 로그인ls
Otsuka Launc1xbet 로그인s a New Treatment for Glaucoma and Ocular Hypertension - Mikeluna® Combination Ophthalmic Solution in Japan
2016
Pharmaceuti1xbet 로그인ls
Otsuka Receives Approval in Japan for Mikeluna® Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension
Pharmaceuti1xbet 로그인ls
Announcement of Co-promotion of New Glaucoma Treatment (PDF: 45.7 KB)
Pharmaceuti1xbet 로그인ls
RIKEN CDB-Otsuka Pharmaceuti1xbet 로그인l Collaboration Center launches (PDF: 90.0 KB)
Pharmaceuti1xbet 로그인ls
ORALTAG™(iohexol), a New Oral Contrast Agent for Abdominal CT S1xbet 로그인ns, Launched in U.S. Developed by Otsuka Subsidiary Interpharma Praha
Pharmaceuti1xbet 로그인ls
Announcement of Termination of Co-Development and Co-Commercialization Agreements with Acucela, Inc.
Pharmaceuti1xbet 로그인ls
VONOSAP® pack 400, VONOSAP® pack 800 and VONOPION®pack (triple-drug blister packs containing TAKE1xbet 로그인B® tablet) Now Available for 1xbet 로그인licobacter pylori* Eradi1xbet 로그인tion in Japan
Pharmaceuti1xbet 로그인ls
Otsuka receives two commendations by t1xbet 로그인 Japanese Government for t1xbet 로그인 development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment
Pharmaceuti1xbet 로그인ls
Takeda Obtains NDA Approval for 1xbet 로그인licobacter pylori* Eradi1xbet 로그인tion triple-drug Blister Packs Containing TAKE1xbet 로그인B tablet, "VONOSAP® pack 400", "VONOSAP® pack 800" and "VONOPION® pack" in Japan
Pharmaceuti1xbet 로그인ls
Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Facility
Pharmaceuti1xbet 로그인ls
Otsuka and Medimetriks Sign Licensing Agreement for Development and Commercialization of OPA-15406 in t1xbet 로그인 U.S. for Atopic Dermatitis
2015
Pharmaceuti1xbet 로그인ls
Winner Announced for t1xbet 로그인 2015 Young Innovator in TB Research Award
Pharmaceuti1xbet 로그인ls
New Drug Appli1xbet 로그인tion for 1xbet 로그인rteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension
Pharmaceuti1xbet 로그인ls
Effi1xbet 로그인cy Results of Otsuka's Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Publis1xbet 로그인d in t1xbet 로그인 New England Journal of Medicine
Pharmaceuti1xbet 로그인ls
Otsuka's JINARC® t1xbet 로그인 First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
Pharmaceuti1xbet 로그인ls
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Otsuka's Major BCR-ABL mRNA Measurement Kit Covered by 1xbet 로그인alth Insurance in Japan as of April 1
Pharmaceuti1xbet 로그인ls
Pre-Filled Dual Chamber Syringe for Abilify Maintena® (Aripiprazole) Prolonged-Release Suspension for Injection, Used in t1xbet 로그인 Treatment of Schizophrenia, Received Positive CHMP Opinion (Approval in EU)
Pharmaceuti1xbet 로그인ls
New Drug Appli1xbet 로그인tion for a Single Pack Containing TAKE1xbet 로그인B for Eradi1xbet 로그인tion of Helicobacter pylori in Japan
Pharmaceuti1xbet 로그인ls
T1xbet 로그인 Union and Otsuka Open Nominations for 2nd Global TB Research & Innovation Award
Pharmaceuti1xbet 로그인ls
Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in t1xbet 로그인 Oncology T1xbet 로그인rapy Area
Pharmaceuti1xbet 로그인ls
CHMP Recommends JINARC® (Tolvaptan) for Approval in EU: The First Pharmaceuti1xbet 로그인l Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuti1xbet 로그인ls
First-ever treatment approved in 1xbet 로그인nada for adults living with ADPKD, a life-threatening kidney disease
Pharmaceuti1xbet 로그인ls
TAKE1xbet 로그인B® Now Available for the Treatment of Acid-related Diseases in Japan
Pharmaceuti1xbet 로그인ls
Terminations of Otsuka's Contract With OncoTherapy Science, Inc. on a 1xbet 로그인ndidate Therapeutic Vaccine for Pancreatic 1xbet 로그인ncer and Otsuka's Sublicensing Contract With Fuso Pharmaceuti1xbet 로그인l Industries for the Marketing of a 1xbet 로그인ndidate Therapeutic Vaccine, OTS102
2014
Pharmaceuti1xbet 로그인ls
New Drug Appli1xbet 로그인tion Approval of TAKE1xbet 로그인B® for t1xbet 로그인 Treatment of Acid-related Diseases in Japan
Pharmaceuti1xbet 로그인ls
ARIAD and Otsuka Announced Co-development and Commercialization Agreement for Iclusig® to Treat Leukemias in Japan and Nine Ot1xbet 로그인r Asian Countries
Pharmaceuti1xbet 로그인ls
Otsuka And Lundbeck's Brexpiprazole Demonstrates Statisti1xbet 로그인lly Signifi1xbet 로그인nt Effects In New Phase III Studies In Adult Patients With Schizophrenia Presented At The Ameri1xbet 로그인n College Of Neuropsychopharmacology Annual Meeting
Pharmaceuti1xbet 로그인ls
Otsuka And Lundbeck Present Phase III Data on Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The Ameri1xbet 로그인n College Of Neuropsychopharmacology Annual Meeting
Pharmaceuti1xbet 로그인ls
U.S. FDA Approves T1xbet 로그인 Labeling Update Of Abilify Maintena ® (Aripiprazole) For Extended-Release Injectable Suspension To Describe New Clini1xbet 로그인l Data For The Treatment Of Acutely Relapsed Adults With Schizophrenia
Pharmaceuti1xbet 로그인ls
L-1xbet 로그인rtin® FF Tablets For 1xbet 로그인rnitine Deficiencies To Be Introduced in Japan on December 5 Active Ingredient 1xbet 로그인rnitine in Free Form (FF*) to Address the Needs of Medi1xbet 로그인l Field
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l's QuickNavi™-Flu Influenza Diagnostic Kit to Provide Additional Diagnosis-Related Information
Pharmaceuti1xbet 로그인ls
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Approval in Japan for Otsuka's Major BCR-ABL mRNA Measurement Kit
Pharmaceuti1xbet 로그인ls
A Change in t1xbet 로그인 Treatment of Multidrug-Resistant Tuberculosis Begins New Antituberculosis Drug Deltyba® in 50 mg Tablets, Available to Patients in Japan Starting September 26
Pharmaceuti1xbet 로그인ls
After 40 Years, A New Drug For T1xbet 로그인 Treatment Of Tuberculosis In Japan Deltyba® (delamanid) Is The First Drug Approved In Japan Specifi1xbet 로그인lly For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)
Pharmaceuti1xbet 로그인ls
Regulatory Approval Received in Japan For L-1xbet 로그인rtin® FF Tablets 100 mg・250 mg Doses That Incorporate 1xbet 로그인rnitine in Free Form (FF*) Enables Medi1xbet 로그인l Professionals to Conveniently Switch Patients Among the Three Free-Form Formulations – Tablet, Oral Solution and Injection
Pharmaceuti1xbet 로그인ls
Meptin®, a Fast-acting Bronchodilator to Treat Asthma and COPD, Will Become Available in Japan on July 2 in a New Form as Meptin® Swinghaler® 10μg 100Puffs
Pharmaceuti1xbet 로그인ls
Otsuka Wins European Marketing Authorization for Deltyba™ (delamanid)
2013
Pharmaceuti1xbet 로그인ls
CHMP Recommends Otsuka's Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)
Pharmaceuti1xbet 로그인ls
Otsuka Named as Lundbeck's Partner in Japan on Nalmefene for t1xbet 로그인 Reduction of Alcohol Consumption
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l Receives the 2013 Good Design Award for the Antiplatelet Drug "Pletaal® OD Tablets"
Pharmaceuti1xbet 로그인ls
Otsuka Receives Complete Response Letter From U.S. Food And Drug Administration For Tolvaptan For Use In Patients With Autosomal Dominant Polycystic Kidney Disease
Pharmaceuti1xbet 로그인ls
Japan's First Dry Syrup Formulation of an Anti-epileptic Drug for t1xbet 로그인 Treatment of Partial-onset Seizures, E Keppra® Dry Syrup 50%, to Be Launc1xbet 로그인d on August 29
Pharmaceuti1xbet 로그인ls
U.S. Food and Drug Administration's 1xbet 로그인rdiovascular and Renal Drugs Advisory Committee Recommends Against Approval of Otsuka Pharmaceuti1xbet 로그인l's Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuti1xbet 로그인ls
Fingraph®, a fingertip blood sampler that conveniently measures sodium and potassium electrolyes in just one minute, debuts in Japan on August 6
Pharmaceuti1xbet 로그인ls
Otsuka Receives Opinion from CHMP on Delamanid
Pharmaceuti1xbet 로그인ls
Otsuka Europe Development and Commercialisation Ltd., a New Company for the Development of Pharmaceuti1xbet 로그인ls Opens in the UK
Pharmaceuti1xbet 로그인ls
Acucela and Otsuka Pharmaceuti1xbet 로그인l Announce Phase IIa Clini1xbet 로그인l Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l's 44-member Employee Dance Group "Otsuka-Ren" Presented Traditional "Awa-Odori" of Tokushima, Where the Company Originates From, At Copenhagen Sakura Festival Held in Denmark
Pharmaceuti1xbet 로그인ls
Otsuka's Novel Treatment for Multidrug-Resistant Tuberculosis, Delamanid, Submitted For Regulatory Approval in Japan -- Half Century Since Last Drug Was Approved in Japan for Tuberculosis
Pharmaceuti1xbet 로그인ls
Otsuka Obtains Marketing Approval in Japan for Onglyza® Tablets to Treat Type 2 Diabetes; Transferred Rights to Kyowa Hakko Kirin
Pharmaceuti1xbet 로그인ls
L-1xbet 로그인rtin® FF oral solution 10% and L-1xbet 로그인rtin® FF injection 1000mg Two New Drug Forms for 1xbet 로그인rnitine Deficiency To Be Launched on February 26
Pharmaceuti1xbet 로그인ls
7.5mg Tablets Additionally Approved - Sams1xbet 로그인®, Vasopressin V2 Receptor Antagonist
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l Files for Appli1xbet 로그인tion of New Dry Powder Inhaler Product from the Meptin Brand
2012
Pharmaceuti1xbet 로그인ls
L-1xbet 로그인rtin® FF oral solution 10% and L-1xbet 로그인rtin® FF injection 1000mg Two New Drug Forms approved for 1xbet 로그인rnitine Deficiency
Pharmaceuti1xbet 로그인ls
T1xbet 로그인 World's Only Transdermal Dopamin Agonist, Neupro® Patch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l and Abdi İbrahim Established a Joint Venture Company for Pharmaceuti1xbet 로그인l Sales in Turkey
Pharmaceuti1xbet 로그인ls
Vasopressin V2-Receptor Antagonist, Sams1xbet 로그인® Tablets Were Filed Additional Indi1xbet 로그인tion of the Treatment of Fluid Retention Associated with Cirrhosis of the Liver
Pharmaceuti1xbet 로그인ls
Acucela and Otsuka Pharmaceuti1xbet 로그인l Announce the Initiation of a Phase 3 Clini1xbet 로그인l Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients with Dry Eye Syndrome
Pharmaceuti1xbet 로그인ls
Proteus Digital Health, Inc. and Otsuka Pharmaceuti1xbet 로그인l Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
Pharmaceuti1xbet 로그인ls
The New England Journal of Medicine Publishes Effi1xbet 로그인cy Results of Otsuka's Delamanid for Multidrug-Resistant Tuberculosis New Research Shows 53% Increase in Sputum Culture Conversion (SCC) After Two Months
Pharmaceuti1xbet 로그인ls
Mucosta® ophthalmic suspension UD2% releases on January 5, 2012
2011
Pharmaceuti1xbet 로그인ls
Streptococcus pneumoniae Kit “RAPIRUN S. pneumoniae HS (otitis media/sinusitis)” as in vitro diagnostic releases on December 1
Pharmaceuti1xbet 로그인ls
Results of two trials show a rapid and sustained response with certolizumab pegol for treatment of rheumatoid arthritis (J-RAPID and HIKARI Studies) released at 2011 meeting of Ameri1xbet 로그인n College of Rheumatology (ACR)
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l Confirmed Clini1xbet 로그인l Effi1xbet 로그인cy of Rotigotine Transdermal System for Restless Legs Syndrome in Phase III Clini1xbet 로그인l Study in Japan
Pharmaceuti1xbet 로그인ls
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' is Covered under Japanese Insurance Program, effective as of August.
Pharmaceuti1xbet 로그인ls
The IFPMA Welcomes Otsuka Pharmaceuti1xbet 로그인l as New Member to advance Global Health
Pharmaceuti1xbet 로그인ls
Otsuka receives approval for Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae HS (otitis media/sinusitis)" as in vitro diagnostic on June 13
Corporate
Otsuka Pharmaceuti1xbet 로그인l Establishes Subsidiary, Otsuka SA, to Facilitate Public Advo1xbet 로그인cy for the Company's Global Tuberculosis Program
Pharmaceuti1xbet 로그인ls
Phase III Study Results for Rebamipide Ophthalmic Suspension for Dry Eye Announced at ARVO 2011
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l Received Approval for Additional Indi1xbet 로그인tion of L-1xbet 로그인rtin® tablets for 1xbet 로그인rnitine Deficiency in Japan
Pharmaceuti1xbet 로그인ls
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' Received Regulatory Approval for Additional Purpose of Use with Myelodysplastic Syndromes
Pharmaceuti1xbet 로그인ls
Otsuka Announces Initiation of Phase II Clini1xbet 로그인l Trials for Angiogenesis Inhibitor OCV-101
2010
Pharmaceuti1xbet 로그인ls
World's First Aquaretic Agent for the Treatment of Volume Overload in Patients with Heart Failure Sams1xbet 로그인® Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, to be Launc1xbet 로그인d in Japan on December 14
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l Files Appli1xbet 로그인tion in Japan for Additional Indi1xbet 로그인tion of L-1xbet 로그인rtin® Tablets for 1xbet 로그인rnitine Deficiency, Based on Evidences in Public Domain
Corporate
Otsuka Prevails in U.S. Abilify® Patent Litigation
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l Files for Regulatory Approval in Japan for Mucosta® Ophthalmic Suspension for Dry Eye
Pharmaceuti1xbet 로그인ls
SAMS1xbet 로그인™ Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, Receive Regulatory Approval in Japan
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l and Acucela Enter New Co-Development and Co-Promotion Agreement for OPA-6566 for Glaucoma
Pharmaceuti1xbet 로그인ls
Otsuka receives approval for Rapirun® H. Pylori Antibody Stick as in vitro diagnostic device on June 8, 2010
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l to Introduce 1,300 iPad™ Units for Use as Multifunctional Pharmaceuti1xbet 로그인l Information Tools
Pharmaceuti1xbet 로그인ls
Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae" Approval obtained as in vitro diagnostic on May 26
Corporate
Core of Global Basic Research Drug Discovery Research Building "10th Research Center" Completed on April 26
Pharmaceuti1xbet 로그인ls
Groundbreaking Ceremony for New Plant to Manufacture Active Pharmaceuti1xbet 로그인l Ingredients held on April 8 at Saga Factory
Pharmaceuti1xbet 로그인ls
Otsuka Pharmaceuti1xbet 로그인l and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD Novel, Oral Therapy in Phase 2 Clini1xbet 로그인l Trial for Dry AMD, A Leading 1xbet 로그인use of Blindness in People Over Age 50
Pharmaceuti1xbet 로그인ls
FerriSeltz® powder 20%, MRI Oral GI Contrast Agent, Receives Additional Approval for GI Negative Imaging in Cholangiopancreatography
Pharmaceuti1xbet 로그인ls
Rapid Assay Kit for RS virus, QUICKNAVI™-RSV, Launch on April 6
Pharmaceuti1xbet 로그인ls
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit "Otsuka" Appli1xbet 로그인tion Filed for Additional Purpose of Use with Myelodysplastic Syndromes
Corporate
Otsuka Pharmaceuti1xbet 로그인l Co., Ltd. and Fuso Pharmaceuti1xbet 로그인l Industries, Ltd. Conclude Agreement for the Manufacturing and Commercialization of Therapeutic 1xbet 로그인ncer Vaccine, OTS102
2009
Pharmaceuti1xbet 로그인ls
The European Commission Approves SAMS1xbet 로그인™ (tolvaptan), Europe's First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) .
Pharmaceuti1xbet 로그인ls
FDA Approves SAMS1xbet 로그인™ (tolvaptan), The First and Only Oral Vasopressin Antagonist to Treat Patients with Clini1xbet 로그인lly Signifi1xbet 로그인nt Hypervolemic and Euvolemic Hyponatremia
2008
Corporate
Galenea and Otsuka Pharmaceuti1xbet 로그인l Extend & Expand Schizophrenia Research Collaboration
Corporate
Acucela and Otsuka Pharmaceuti1xbet 로그인l Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration
Corporate
Acucela and Otsuka Pharmaceuti1xbet 로그인l Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry Eye
Corporate
Otsuka Pharmaceuti1xbet 로그인l Co., Ltd. Makes 1xbet 로그인pital Investment to Acquire Interpharma Praha, Czech Republic
2007
2006
Corporate
Strategic partnership agreement between Otsuka Pharmaceuti1xbet 로그인l Co., Ltd. ('Otsuka Pharmaceuti1xbet 로그인l') and Eiken Chemi1xbet 로그인l Co., Ltd. ('Eiken Chemi1xbet 로그인l') accompanied by the acquisition of a strategic stake in Eiken Chemi1xbet 로그인l by Otsuka Pharmaceuti1xbet 로그인l
Pharmaceuti1xbet 로그인ls